research
< (From Left) Dr. Andrew J. Lee, Dr. Sunwoo Min, Ph.D. student Su Chan Park, Professor Ji Min Lee, Professor Inkyung Jung >
Anti-angiogenic therapies targeting VEGF have been widely used in cancer treatment, yet their long-term efficacy remains limited. Tumor vascular endothelial cells (TECs) exhibit high adaptive plasticity, enabling them to resist treatment and sustain tumor growth, but the molecular mechanism underlying this plasticity has remained poorly understood.
KAIST, led by President Kwang Hyung Lee, announced that a joint research team led by Professor Inkyung Jung (Department of Biological Sciences), Professor Ji Min Lee (Graduate School of Medical Science and Engineering), and Professor Gou Young Koh (Institute for Basic Science) has now uncovered the answer. By integrating cross-cancer single-cell transcriptomic and epigenomic atlases across eight solid tumor types with multiomic profiles, including 3D chromatin contact maps, of human embryonic stem cell (hESC)-derived vascular endothelial cell differentiation, the team demonstrated that TECs reactivate a gene regulatory program normally confined to the late progenitor stage of vascular development. Much like reusing an old blueprint rather than drawing up a new one, tumors co-opt this pre-existing developmental program to fuel blood vessel growth.
The team’s integrative framework combined single-cell RNA-seq and ATAC-seq across multiple tumor types with H3K27ac ChIP-seq, Hi-C-based 3D chromatin mapping across a dense time series of hESC-to-EC differentiation. This approach resolved the EC-progenitor specific regulatory program that defines the shared pro-angiogenic program between late EC progenitors and TECs.
Within this framework, integrin receptor (ITGAV) emerged as a functional mediator specifically upregulated in both late EC progenitors and TECs. Cell-to-cell interaction analysis identified multiple key ligands from tumor micro enviroment (TME) that reactivate the progenitor-associated gene regulatory program. Pharmacologic inhibition attenuated endothelial migration, invasion, and tube formation in vitro, and significantly reduced tumor vascularization and growth in a colorectal cancer xenograft model in vivo.
< Figure. Research Overview: A New Therapeutic Strategy and Target Validation Based on the Discovery That Tumors Co-opt Gene Regulatory Programs Already Present in Normal Vascular Differentiation to Grow Blood Vessels >
Professor Inkyung Jung noted that this study reframes how we understand tumor angiogenesis: tumors do not invent new mechanisms, but exploit regulatory programs already embedded in normal vascular development. This insight offers a new conceptual basis for why anti-VEGF therapies face limitations, and points toward targeting the underlying regulatory architecture of endothelial plasticity as a complementary anti-angiogenic strategy.
The study was co-first authored by Dr. Andrew J. Lee, Dr. Sunwoo Min, Ph.D. student Su Chan Park; and Dr. Mei-Yu Qiu. Professors Inkyung Jung, Ji Min Lee, and Gou Young Koh served as corresponding authors. The findings were published on June 8 in Cancer Research [IF = 22.3].
※ Paper title: "A Co-opted Developmental Gene Regulatory Program in Endothelial Progenitors Promotes Tumor Angiogenic Phenotypes"
※ DOI: 10.1158/0008-5472.CAN-25-5094
※ Authors: Andrew J. Lee (KAIST, first author), Sunwoo Min (KAIST, co-first), Su Chan Park (KAIST, co-first), Mei-Yu Qiu (IBS, co-first), Gou Young Koh (IBS, co-corresponding), Ji Min Lee (KAIST, co-corresponding), Inkyung Jung (KAIST, corresponding)
This research was supported by the National Research Foundation of Korea and the Institute for Basic Science.
-
research KAIST Develops Core Technology to Reverse Biological Changes Once Thought Irreversible, Opening New Possibilities for Aging and Cancer Research
Once a cell has locked into an abnormal state — the way cancer cells do — can it ever be restored back to normal? A KAIST research team has identified the ‘molecular lock’ that keeps cells trapped in an altered state, opening a new path toward releasing that lock and reversing a cell’s fate. KAIST (President Choongsik Bae) announced on the 21st of August that a research team led by Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering has, for t
2026-08-21 -
research Patient-Specific "Blood–Brain Tumor Barrier Chip" Predicts How Glioblastoma Patients Will Respond to Treatment
Even for the same brain tumor treated with the same anticancer drug, the effect can differ from patient to patient. A Korean research team has developed a chip that recreates a patient's own tumor cells together with the surrounding peritumoral vascular environment, making it possible to predict patient-specific treatment responses in advance. KAIST (President Choongsik Bae) announced on August 18 that a research team led by Professor Song Ih Ahn from the Department of Mechanical Engineering,
2026-08-18 -
research KAIST Develops a Way to Combat Cancer Cachexia, the Wasting Syndrome That Debilitates Patients
A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away. A KAIST research team has developed an RNA-based therapeutic strategy that blocks a brain signal to prevent muscle loss and extend survival. KAIST (President Choongsik Bae) announced on the 2nd of August that a joint research team led by Professor Minho Shong and Professor Jinkuk Kim from the Graduate School of Medical Science and Engineering, together with the KAI
2026-08-03 -
research KAIST Makes Cancer Cells Send Out Their Own Danger Signal — Delivering Immunotherapy and Gene Therapy in a Single Nanoparticle Platform
Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signal—prompting immune cells to attack—while simultaneously delivering gene therapy. The approach is expected to offer a new treatment strategy that combines cancer immunotherapy and gene therapy in a single nanoparticle. Immunogenic cell death (ICD) is a process in which dying cancer cells send dange
2026-07-28 -
research KAIST identifies a molecular “switch” that activates cell growth signaling, suggesting a potential basis for next-generation anticancer therapy
Cells carry their own growth switches. When enough nutrients—amino acids in particular—are available, cells flip this switch on and begin to grow. Researchers at KAIST and Yonsei University have now uncovered the molecular mechanism by which amino acid signals activate this cellular growth switch. The findings are expected to open a new avenue for anticancer therapies that target abnormal growth signaling in tumor cells. KAIST (President Choongsik Bae) announced on July 26 that a
2026-07-27